Akcea, Fresh Off C-Suite Shakeup, Dishes Heart Drug to Pfizer for $250M

Pfizer this morning bought an experimental heart disease drug from Akcea therapeutics, the first move made by the Ionis Pharmaceuticals spinout since the company overhauled its management team last month.